“In my opinion, and I think in the opinion of many of my colleagues, there is a complete lack of transparency about how this decision is being made and who is making it,” said Daniel Kaul, an infectious disease physician at the University of Michigan. His hospital’s pharmacy department informed him that their center wouldn’t be getting any doses of remdesivir after being in contact with the drug’s private distributor, AmerisourceBergen, earlier on Wednesday.
“Those of us on the frontlines treating people with Covid-19 need to know what the criteria are and where this drug is going to be available and why those places were selected,” he went on.“All of us want to make sure limited resources are used in the most efficient fashion. … The government entity making this decision should reveal itself and it should state its criteria.”
Even medical centers chosen to receive the drug were in the dark. “I legitimately do not have any insight into how hospitals were selected,” said Paul Biddinger, director of Massachusetts General Hospital’s Center for Disaster Medicine and one of the leaders of the hospital’s pandemic response.